Table 4.
Characteristics of Patients Responding to Veliparib/Temozolomide Treatment
| DL | Age/Sex | Disease | Prior treatment | Karyotype | Response | Cy | Off Study |
|---|---|---|---|---|---|---|---|
| 1A | 71F | AML | 7+3, HiDACx3-CR1 of 33 months (mos); Relapse-ara-C+Chk1 inhibitor-NR | 46, XX; FLT3-ITD and NPM1 mut | CR | 4 | For alloSCT but 4 mos delay -Relapse |
| 2 | 70F | AML from MDS | MDS-AZAx19; DECx2-SD; transformed to AML- 7+3- NR; SAHA-HiDAC+etoposide-NR | 46, XX, t(3;5) (q25;q33) | CR | 3 | Relapse |
| 3 | 76F | t-AML from MDS | Hx of t(8;21)AML s/p 7+3 and tipifarnib but developed t-AML from MDS 19 mos later | 46, XX | CR | 4 | Relapse |
| 4 | 64F | AML | AcDVP-16-NR AZAx5-NR |
46, XX, del(7)(q32) | CR | 3 | NMA alloSCT- still in CR |
| 4 | 61M | AML from MDS | Flavopiridol+ara-C-NR | Complex (>5) | CR | 2 | NMA alloSCT-Relapse 3 mos later |
| 5 | 63M | AML from CMMoL | Induction chemo and NMA alloHSCT-CR; relapse 39 mos later-AZAx20 and DLIx2 | 46, XY | CRp post Cy1 but CR post Cy2 | 2 | DLI and then NMA alloSCT |
| 5 | 64M | AML | AcDVP-16/NMA alloHSCT-CR1 of 41 mos; AcDVP-16 + AZA-CR2 of 3 mos; 2nd relapse | 46,XY,t(2;21)(p11.2;p11.2),t(13;15)(q34;q22) | CR post Cy2 | 2 | Due to histoplasmosis; received anti-CD123 Abx6 in CR |
| 5 | 70M | AML from MDS | AZA+etinostatx2-NR | Complex (>5) Inv(3) |
CR | 4 | PD |
| 1A | 62M | AML from MDS | AZAx18 for MDS then transformed to AML | 46, XY | HI-clearance of PB and decrease in BM blasts; stable counts | 6 | PD |
| 1B | 73F | AML from CMML | Triapine+Fludarabinex4-PD on HU | 46, XX | SD/HI-reduction and stabilization of WBC; clearance of circulating blasts | 3 | PD |
| 2 | 71F | AML from CMML | Triapine+Fludarabinex2-PD on HU | 46, XX | SD/HI-reduction and stabilization of WBC; reduction in circulating blasts | 7 | PD |
| 3 | 73M | AML from MDS | MTX/dexamethasone/G-CSF for MDS-transformed to AML-AZAx5-NR; Clofarabine ×1-NR | 46, XY | SD-WBC count stabilization | 3 | PD |
| 4 | 70F | AML from MDS | AZAx2 for MDS-transformed to AML on HU | 47, XX, +8 | HI-marrow PR and clearance of circulating blasts | 2 | PD |
| 4 | 70M | AML from MPN/MDS | AZAx15, Revlimid × 1, Onconova × 6 for MDS-transformed to AML on HU | 46, XY | HI-clearance of circulating blasts, increase ANC, platelets stable | 3 | PD |
| 6 | 75F | AML from MDS | Epogen/G-CSF; AZAx10 for MDS-transformed to AML | 46, XX | HI- marrow CR | 2 | PD |
| 5 | 75M | AML from MDS | AZAx12 for MDS-transformed to AML-Revlimid-NR; Clofarabinex1-NR | 47, XY, del(3)(q12q21), +8 | SD/HI-disease stabilization and decrease in BM blasts | 2 | PD |
Abbreviations: M-male; F-female; HiDAC-high dose cytarabine; AZA-azacitidine; DEC-decitabine; ACDVP-16-cytarabine, daunorubicin, etoposide; MTX-methotrexate; HU- hydroxyurea; DLI- donor lymphocyte infusion; CR-complete remission; CRp-CR with incomplete platelet recovery; NR-no response; HI-hematologic improvement; SD-stable disease; PD- progressive disease; NMA- non myeloablative; WBC- white blood cell